RvD1 accelerates the resolution of inflammation by promoting apoptosis of the recruited macrophages via the ALX/FasL-FasR/caspase-3 signaling pathway
Autor: | Yang Ye, Fang-gao Smith, Qian Yang, Shao-wu Jin, Shengxing Zheng, Qian Wang, Hao ran Xu, Shengwei Jin, Min-qi Ma, Chen-xi Shen, Shu-Yang Xiang, Hong-Xia Mei |
---|---|
Rok vydání: | 2021 |
Předmět: |
Cancer Research
ARDS Lipopolysaccharide Respiratory distress syndrome Immunology Inflammation Caspase 3 Lung injury Fas ligand Article Cellular and Molecular Neuroscience chemistry.chemical_compound medicine Macrophage Acute inflammation RC254-282 QH573-671 business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cell Biology medicine.disease chemistry Apoptosis medicine.symptom business Cytology |
Zdroj: | Cell Death Discovery Cell Death Discovery, Vol 7, Iss 1, Pp 1-10 (2021) |
ISSN: | 2058-7716 |
Popis: | The uncontrolled inflammatory response caused by a disorder in inflammation resolution is one of the reasons for acute respiratory distress syndrome (ARDS). The macrophage pool markedly expands when inflammatory monocytes, known as recruited macrophages, migrate from the circulation to the lung. The persistent presence of recruited macrophages leads to chronic inflammation in the resolution phase of inflammation. On the contrary, elimination of the recruited macrophages at the injury site leads to the rapid resolution of inflammation. Resolvin D1 (RvD1) is an endogenous lipid mediator derived from docosahexaenoic acid. Mice were administered RvD1 via the tail vein 3 and 4 days after stimulation with lipopolysaccharide. RvD1 reduced the levels of the inflammatory factors in the lung tissue, promoted the anti-inflammatory M2 phenotype, and enhanced the phagocytic function of recruited macrophages to alleviate acute lung injury. We also found that the number of macrophages was decreased in BAL fluid after treatment with RvD1. RvD1 increased the apoptosis of recruited macrophages partly via the FasL-FasR/caspase-3 signaling pathway, and this effect could be blocked by Boc-2, an ALX/PRP2 inhibitor. Taken together, our findings reinforce the concept of therapeutic targeting leading to the apoptosis of recruited macrophages. Thus, RvD1 may provide a new therapy for the resolution of ARDS. |
Databáze: | OpenAIRE |
Externí odkaz: |